DIRECT TARGETING OF THE FKBP52 COCHAPERONE FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER

$408,843FY2017Department of the ArmyDOD

Clark Atlanta University, Inc.

Investigators